Amylin Pharmaceuticals

Abilita Bio Appoints Dan Bradbury to its Newly Formed Board of Directors

Retrieved on: 
Wednesday, February 23, 2022
Amylin, Therapy, Board of directors, EMP, Chronic pain, Board, Diabetes, Shareholder, Amylin Pharmaceuticals, Education, Bristol Myers Squibb, Director, Antibody, United Kingdom, CA, LLC, Hope, Lists of diseases, Acquisition, G protein-coupled receptor, University of Nottingham, Multimedia, Ion, Membrane protein, SAN, Cancer, Nasdaq, Intercept Pharmaceuticals, Patient, Marketing, Management, CEO, Research, Bachelor of Pharmacy, Pharmaceutical industry, Pharmacy

SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- Abilita Bio, Inc., today announced the appointment ofDaniel M. Bradbury to its Board of Directors.

Key Points: 
  • SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- Abilita Bio, Inc., today announced the appointment ofDaniel M. Bradbury to its Board of Directors.
  • Mr. Bradbury is a seasoned biotech executive and business strategist with a formidable track record of building successful biotech companies.
  • Dan brings a wealth of biotech leadership and clinical experience to the table along with his sharp strategic thinking.
  • Mr. Bradbury serves on the Board of Directors of Biocon Limited , Castle Biosciences, Inc. , Equillium, Inc., Intercept Pharmaceuticals, Inc. and a number of private companies and philanthropic organizations.

PreludeDx™ Announces the Appointment of Derek J. Maetzold of Castle Biosciences to its Board of Directors

Retrieved on: 
Wednesday, February 2, 2022
CEO, Breast, Risk, Patient, George Mason University, University, University of California, San Francisco, Cancer, National, Physician, Molecular biology, National Cancer Institute, FCB, Compugen (Israeli company), Twitter, Technology, Adoption, Board of directors, Woman, Research, Board, Instagram, Recurrence, Program, Schering-Plough, DCIS, Biomarker, Precision medicine, Company, Risk assessment, University of California, Riverside, AstraZeneca, Ductal carcinoma, Amylin Pharmaceuticals, Breast cancer, LinkedIn, MBA, Convergence of random variables, Management, Medical imaging, Pharmaceutical industry, Biology, Pfizer, Facebook, Merck, Novartis

"I am pleased to welcome Derek to our Board of Directors.

Key Points: 
  • "I am pleased to welcome Derek to our Board of Directors.
  • "I am impressed with PreludeDx's DCISionRT test, the only test that predicts radiation therapy benefit and risk of recurrence for ductal carcinoma in situ (DCIS) breast cancer patients," said Derek J. Maetzold.
  • Mr. Maetzold spent the 24 years prior to founding Castle Biosciences in the pharmaceuticals with a focus on business licensing and commercial oversight of pre-approved therapies.
  • For more information on how PreludeDx is making a difference for patients, please visit the Company's website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.

ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of Directors

Retrieved on: 
Wednesday, January 19, 2022
Duke University School of Medicine, Patient, Accounting, Brigham, Associate, Hypoglycemia, LinkedIn, Amylin Pharmaceuticals, SAN, Hypertension, Board of directors, Cell encapsulation, CRISPR Therapeutics, Protein, LLP, W. L. Gore & Associates, Leadership, Virtual College of Biotechnology, University of Saskatchewan, Regenerative medicine, History of the College of William & Mary, View, Duke University Hospital, Industry, Therapy, Brigham and Women's Hospital, Diabetes, Company, Drug development, GlaxoSmithKline Pharmaceuticals Ltd, Hospital, University, Multimedia, Type 2 diabetes, Potency (pharmacology), Risk, PricewaterhouseCoopers, Twitter, College, Senior, Board, Pharmaceutical industry, Management, Exenatide, Facebook, Operation, Endocrinology

"We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte.

Key Points: 
  • "We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte.
  • "I am excited to lead the finance team as we pursue significant clinical and growth opportunities to create increased value across our pipeline."
  • Previously, Ms. Levin was Chief Financial Officer at Bird Rock Bio, a clinical-stage bio-pharmaceutical company focused on the treatment of fibrotic, metabolic and inflammatory diseases.
  • Prior to Nano Precision Medical, Dr. Porter was Chief Medical Officer for Eiger Biopharmaceuticals, Inc. and Dance Biopharma, Inc. (now Aerami Therapeutics).

IDEOlogy Health Appoints Cameron Lush, Ph.D. as Chief Commercial Officer

Retrieved on: 
Tuesday, January 18, 2022
Patient, Conference, Amylin Pharmaceuticals, Biotechnology, US, Genentech, Growth, Leadership, Health, Industry, Marketing, Ideology, Organization, Physician, Pharmaceutical industry, Medicine, Physiology, Western University, Exelixis

AUSTIN, Texas, Jan. 18, 2022 /PRNewswire/ -- IDEOlogy Health, a leading medical education company, announced that Cameron Lush will join the company as Chief Commercial Officer effective today.

Key Points: 
  • AUSTIN, Texas, Jan. 18, 2022 /PRNewswire/ -- IDEOlogy Health, a leading medical education company, announced that Cameron Lush will join the company as Chief Commercial Officer effective today.
  • In his role as Chief Commercial Officer, Cameron will lead IDEOlogy's commercial team including IDEOlogy's rapidly growing medical education division and supporting services, the launch of IDEOlogy's Medical Conference division, and the growth of our strategic collaborations.
  • "I am excited to welcome Cameron to IDEOlogy's leadership team as we look forward to expanding our commercial operations and delivering on our multiple strategic partnerships," said Mike Gramling, Chief Executive Officer of IDEOlogy.
  • IDEOlogy Health is the industry leader for delivering unbiased medical education of scientific and clinical data to healthcare professionals.

Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen

Retrieved on: 
Monday, January 10, 2022
GMP, IPO, Drug discovery, MCRPC, SAN, Growth, Takeda, University of Minnesota Law School, LinkedIn, Amylin Pharmaceuticals, Investor relations, ASCO, Takeda Pharmaceutical Company, Security (finance), Leadership, Patient, Compugen (Israeli company), Board, IND, U.S. Securities and Exchange Commission, Minot State University, Transposase, Lung, Partnership, University, Multimedia, Prostate cancer, Therapy, Research, CEO, Senior, OTC, Company, Private Securities Litigation Reform Act, Corporate development, Nasdaq, AAV, Technology, Breast, Biotechnology, FDA, Board of directors, Corporation, Twitter, Webcast, Medtronic, Population, Genetic engineering, Management, Pharmaceutical industry, Gergen

Poseida announces President Mark Gergen to serve as CEO, effective 2/1.

Key Points: 
  • Poseida announces President Mark Gergen to serve as CEO, effective 2/1.
  • Under his leadership, Poseida grew to over 250 employees, raised significant private capital and successfully completed an IPO in 2020.
  • The partnership Eric and I have built in guiding the company will continue," said Mark Gergen, Poseida's President and Chief Business Officer.
  • These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect.

Dr. Hubert Chen Joins ADARx Pharmaceuticals as Chief Medical Officer

Retrieved on: 
Wednesday, January 5, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Therapy, University, Liver, Endocrinology, Research, Patient, Hospital, University of California, San Francisco, Gladstone Institutes, Medicine, Oligonucleotide, Cardiovascular disease, Teriparatide, Internal medicine, Degenerative disease, Massachusetts General Hospital, Peripheral nervous system, RNA, Amgen, Regulus Therapeutics, Amylin Pharmaceuticals, Columbia University, Leadership, Pharmaceutical industry, EU

ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA-targeting therapeutics, today announced the appointment of Hubert C. Chen, M.D.

Key Points: 
  • ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA-targeting therapeutics, today announced the appointment of Hubert C. Chen, M.D.
  • We are delighted to have Hubert join ADARx at such a pivotal moment in our companys growth, said Dr. Zhen Li, President and Chief Executive officer of ADARx.
  • He previously served as the Chief Medical Officer of Metacrine, a clinical-stage company focused on the treatment of liver and gastrointestinal diseases.
  • ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics.

Cognex Appoints New Board Member

Retrieved on: 
Thursday, November 4, 2021
Manufacturing, Engineering, Audit committee, Business Insider, News, Form 10-K, NASDAQ, Knowledge, Cognex Corporation, Failure, Yahoo!, Amylin Pharmaceuticals, Growth, Farallon Capital, Artificial intelligence, EGroups, LLC, Sale, Board, Vanderbilt University, Biotechnology, Stanford University, QuinStreet, SEC, Woman, Diabetes, Corporation, Nasdaq, CGNX, Audit

Cognex Corporation (NASDAQ: CGNX) today announced the appointment of Marjorie T. Sennett to Cognexs Board of Directors, effective immediately.

Key Points: 
  • Cognex Corporation (NASDAQ: CGNX) today announced the appointment of Marjorie T. Sennett to Cognexs Board of Directors, effective immediately.
  • We are excited for Marjorie to join our board, said Anthony Sun , Chairman of Cognex.
  • Her public board experience, extensive knowledge of corporate finance and financial reporting, financial leadership for fast-growing companies in the biotechnology and technology sectors, and experience as an institutional investor will be a valuable asset to Cognex.
  • Ms. Sennett currently serves as a member of the Board of Directors and Chair of the Audit Committee of The diaTribe Foundation, a private entity focused on improving the outcomes of people with diabetes.

Seraphina Therapeutics Receives Infusion of Capital to Meet Market Demand for Breakthrough Cellular Health Ingredient FA15™

Retrieved on: 
Wednesday, October 13, 2021
CFO, Navy, Fats, Food, Ageing, Transformation/transcription domain-associated protein, Heart, Johns Hopkins, Risk, Growth, Cardiovascular disease, The Vitamin Shoppe, Mortality, Therapy, USPTO, Institute of Liver and Biliary Sciences, Health, Billiard ball, Science, GLOBE, Â, GRAS, Harvard University, SAN, Benvolio, CEO, Cue Ball Capital, Happy Family, Amylin Pharmaceuticals, Global health, Patent, DTC, Heart failure, Quality of life, Pharmaceutical industry, Dietary supplement

“After discovering the first essential fatty acid in over 90 years, the excitement of the monumental discovery quickly changed from a once-in-a-life-time, science moment to a purpose-driven obligation to advance global health -- specifically, to promote preventative health and stem the rise of metabolic, heart and liver diseases,” said Stephanie Venn-Watson, CEO and co-founder of Seraphina Therapeutics. “As we continue to see greater demand for FA15TM, we are thrilled to see a growing body of independent studies from around the world supporting the critical role of C15:0 in maintaining our long-term health.”

Key Points: 
  • The new capital is being led by Domain Associates , Benvolio Group with prior Coach CEO, Lew Frankfort and prior Vitamin Shoppe CFO, Larry Segall, and Cue Ball Capital .
  • The companys hero offering is the worlds first C15:0 (pentadecanoic acid) essential fatty acid supplement, better known as fatty15 .
  • Using FA15TM, Seraphinas proprietary pure powder and vegan friendly C15:0 ingredient, the Seraphina team aims to positively affect physiological changes relevant for optimal cardiometabolic, immune, and liver health.
  • Seraphina Therapeutics, Inc. is a health and wellness company dedicated to advancing global health through the discovery of essential fatty acids and micronutrient therapeutics.

Poseida Therapeutics Announces Leadership Appointments

Retrieved on: 
Wednesday, October 13, 2021
People, Leadership, LLP, U.S. Securities and Exchange Commission, Venture round, University, Human resources, AAV, Technology, Genetic engineering, Administration, Bowling Green State University, Bachelor of Accountancy, Takeda, Nasdaq, IND, LinkedIn, Private Securities Litigation Reform Act, Senior, Cancer, Michigan State University, Growth, Medtronic, Facility, Molecular biology, Transposase, Security (finance), Research and development, Ursinus College, Multimedia, Grant Thornton International, Patient, Regulatory affairs, Neurocrine Biosciences, Science, Perelman School of Medicine at the University of Pennsylvania, Cell, Pathology, SAN, Company, Perrigo, Amylin Pharmaceuticals, Twitter, Certified Public Accountant, Therapy, Research, Partnership, Communication, T cell, Management, Pharmaceutical industry

SAN DIEGO, Oct. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced appointments to new roles on its executive leadership team.

Key Points: 
  • SAN DIEGO, Oct. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced appointments to new roles on its executive leadership team.
  • She holds a Bachelor of Accountancy degree from the University of San Diego and is a Certified Public Accountant.
  • Ms. Martin most recently served as Chief Human Resources Officer upon joining Poseida in 2019.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.

Alcami Announces Parenteral Operations Leadership Appointments

Retrieved on: 
Tuesday, October 12, 2021
Calibration, Air force, Engineering, Grand River Aseptic Manufacturing, Microbiology, Multimedia, United, Pfizer, Madison Dearborn Partners, Metrology, CDMO, Technical Service Council, Amylin Pharmaceuticals, Leadership, Cardinal Health, Manufacturing operations, View, Management, Fine chemical

Chad Bovero has been appointed to the role of Vice President, Charleston Sterile Operations.

Key Points: 
  • Chad Bovero has been appointed to the role of Vice President, Charleston Sterile Operations.
  • "Chad, James, and Tobin bring technical expertise, proven leadership experience, and operational excellence," commented Patrick Walsh, Chairman and Chief Executive Officer at Alcami.
  • Chad Bovero, Vice President of Charleston Parenteral Operations, began his career in the United States Air Force as a Calibration Technician and brings a depth of technical expertise and a track record of leading sterile manufacturing operations.
  • Before joining Alcami in July, Mr. Bovero was the Director of Operations at LSNE Contract Manufacturing.